David Franks - Novacyt SA Chief Officer

All Insiders . USA . 
Stock . Novacyt SA . Stakeholders . Insider . David Franks
NVYTF Stock  USD 0.64  0.06  8.57%   

Insider

David Franks is Chief Officer of Novacyt SA
Phone33 1 39 46 51 04
Webhttps://www.novacyt.com

Novacyt SA Management Efficiency

The company has return on total asset (ROA) of 0.0145 % which means that it generated a profit of $0.0145 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0198) %, meaning that it generated substantial loss on money invested by shareholders. Novacyt SA's management efficiency ratios could be used to measure how well Novacyt SA manages its routine affairs as well as how well it operates its assets and liabilities.
Novacyt SA has accumulated 1.67 M in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Novacyt SA has a current ratio of 4.57, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Novacyt SA until it has trouble settling it off, either with new capital or with free cash flow. So, Novacyt SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novacyt SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novacyt to invest in growth at high rates of return. When we think about Novacyt SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Shunichi KurodaBone Biologics Corp
N/A
John WilsonRapid Micro Biosystems
56
Micah MitchellMyomo Inc
48
Blake GurfeinTivic Health Systems
40
Robert CarlsonBiomerica
N/A
Harry MDMyomo Inc
65
Sunil SawhneyAethlon Medical
N/A
Dennis RosenbergSemler Scientific
70
Steven MDAethlon Medical
56
CPA CPACytosorbents Crp
67
M HarrisonNanoVibronix
N/A
Aron TendlerBrainsway
N/A
Odelya DekelInspira Technologies Oxy
N/A
Danielle WatsonHeart Test Laboratories
42
Hans BoehringerBiomerica
N/A
Ryan SabiaTivic Health Systems
37
CPA CPANanoVibronix
68
Pr ZangenBrainsway
54
Daniella YeheskelyHayonInspira Technologies Oxy
47
Sanjay AhujaTivic Health Systems
N/A
Rony AloniInspira Technologies Oxy
N/A
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Vlizy-Villacoublay, France. Novacyt operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 210 people. Novacyt SA [NVYTF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity-0.0198
Return On Asset0.0145

Novacyt SA Leadership Team

Elected by the shareholders, the Novacyt SA's board of directors comprises two types of representatives: Novacyt SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novacyt. The board's role is to monitor Novacyt SA's management team and ensure that shareholders' interests are well served. Novacyt SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novacyt SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Steve Gibson, Group Controller
David Franks, Chief Officer
Grald Ulrich, Chief Devel
James McCarthy, Acting CFO
Bryan Close, Chief Officer
Wendy Karban, Group Mang
Paul Oladimeji, Group RD

Novacyt Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novacyt SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.0198
Return On Asset0.0145
Profit Margin(0.1) %
Operating Margin0.07 %
Current Valuation(50.49 M)
Shares Outstanding70.63 M
Shares Owned By Insiders3.49 %
Shares Owned By Institutions1.60 %
Price To Earning0.51 X
Price To Book0.40 X

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Novacyt Pink Sheet

Novacyt SA financial ratios help investors to determine whether Novacyt Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novacyt with respect to the benefits of owning Novacyt SA security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY